Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

major thrombotic cardiovascular events

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

R&D productivity takes off

Approvals of NMEs reach heights last seen in the mid-1990s

- PMLiVE

Merck faces another Bridion knockback

It is seven years since the FDA initially rejected it

- PMLiVE

Keytruda is UK’s first early-access medicine

Merck’s melanoma therapy accepted under the UK’s EAMS

- PMLiVE

US approval for Astellas’ new antifungal drug Cresemba

Japanese firm co-markets the azole antifungal agent with Basilea

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

FDA launches drug shortages mobile app

USregulator offers the public and HCPs Android and iPhone versions of the app

- PMLiVE

Merck rode out rival to sign $450m deal with NGM

Part of a five-year alliance on metabolic disorders and cancer

- PMLiVE

Apotex latest to file Neupogen biosimilar in the US

White blood cell stimulator could be on the market this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links